New drug duo aims to shrink tough bladder tumors before surgery
NCT ID NCT06263153
Summary
This study is testing a combination of two drugs, futibatinib and durvalumab, given to patients before they have surgery to remove their bladder (cystectomy). The goal is to see if this treatment can shrink or eliminate the cancer in the bladder before it is surgically removed. It is for patients with muscle-invasive bladder cancer who are not eligible for the standard cisplatin chemotherapy due to other health issues like kidney problems or heart failure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Taussig Cancer Center
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Michigan Comprehensive Cancer Center
WITHDRAWNAnn Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.